


Docket No.



JC10 Rec'd PCT/PTO 18 JUL 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Horst BAUER, et al.

SERIAL NO: 10/529,203

GAU:

FILED: March 25, 2005

EXAMINER:

FOR: ADMINISTRATION FORM FOR PHARMACEUTICALLY ACTIVE PEPTIDES WITH SUSTAINED RELEASE OF ACTIVE INGREDIENTS, AND METHOD FOR THE PRODUCTION THEREOF

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

**Corwin P. Umbach, Ph.D.**  
**Registration No. 40,211**


Surinder Sachar

Registration No. 34,423

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

268034US0PCT

SERIAL NO.

10/529,203

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Horst BAUER, et al.

FILING DATE

March 25, 2005

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5 595 760	01/21/97	CHERIF-CHEIKH			
	AB	5 916 582	06/29/99	STEVENSON et al.			
	AC	5 411 951	05/02/95	MITCHELL			
	AD	2002/0065226	05/30/02	SILER-KHODR			
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	99/48517	09/30/99	WO (with English abstract)		NO
	AP					
	AQ					
	AR					
	AS					
	AT					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AU	JIANG, Guangcheng et al. "Betidamino Acid Scan of the GnRH Antagonist Acyline", J. Med. Chem., vol. 40, pages 3739-3748, XP002071836 1997				
	AV	MIZUGUCHI, K. et al. "Phase III clinical trial of ICI 118,630(Zoladex) depot for hysteromyoma. Randomized non-blind comparative test using symptomatic treatment as a control", Sanfujinka no Sekai, vol. 47, pages 229-257, English abstract only, STN Search 1995				
	AW	"Information to supplement the report on endometriosis", <a href="http://www.wdr.de/tv/frautv/archiv2001/f21060_e.html">http://www.wdr.de/tv/frautv/archiv2001/f21060_e.html</a> , with English translation 2001				
	AX	"Hormones and antihormones", Excerpts from Handbuch Medikamente, 3 <sup>rd</sup> edition, <a href="http://home.t-online/home/koubenec/brustkrebs-therapie/chemo-hormone.htm">http://home.t-online/home/koubenec/brustkrebs-therapie/chemo-hormone.htm</a> , with English translation 2000				
	AY	SCHWARZ, H. P. "Do all forms of precocious puberty require treatment?", Scientific Meeting of the Working Group on the Occasion of the 54 <sup>th</sup> Congress of the German Society of Gynecology and Obstetrics (DGGO), <a href="http://www.kindergynaekologie.de/html/themen.html">http://www.kindergynaekologie.de/html/themen.html</a> , with English translation 2002			<input type="checkbox"/> Additional References sheet(s) attached	

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. PCT Application Serial No.: 10/529,203  
Docket No.: 268034US0PCT

#### STATEMENT OF RELEVANCY

- 1) References AA-AC, AO, AU have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References AD, AV-AY have been cited in the corresponding German Search Report. A copy of these references is being submitted herewith.
- 3) References \_\_\_\_\_ are discussed in the specification. A copy of these references is being submitted here with.
- 4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.